Checklist · Commercial

Substantiating Advertising Claims: A Practical Checklist

15 U.S.C. § 1125(a)

Type
Checklist
Jurisdiction
National
Date
2024-10-14
Topic
Commercial

Every objective claim in an advertisement must be supported by adequate substantiation that exists in the advertiser's hands before the ad runs — not after a regulator or a competitor asks. This checklist walks a claim-review team through the full pre-publication workflow: inventorying every express and implied claim, fixing the net impression a reasonable consumer would take away, classifying each claim as puffery, an ordinary objective claim, an establishment claim, or a health and safety claim, and then matching each to the level of support the law requires. It covers the "competent and reliable scientific evidence" standard for efficacy claims, the testing you must actually have run before saying "3x faster," the methodological rules for consumer surveys and expert support, and the clear-and-conspicuous requirements that make disclosures work rather than decorate the page. Special-claim regimes — Made in USA, environmental benefit, pricing, and "free" — get their own gates. The document closes with an approval and versioning workflow, a Common Mistakes section, and a consolidated one-glance checklist you can run against any campaign. Authority runs from FTC Act §§ 5 and 12 and the 1984 Substantiation Policy Statement through Lanham Act § 43(a) and the establishment-claim cases.

Substantiating Advertising Claims: A Practical Checklist

Commercial > Advertising and Marketing | Published 14 October 2024 - Updated 5 December 2025 | UpLaw - uplaw.us

The question is never whether you can defend the claim. The question is whether you could have defended it on the morning the ad ran. Substantiation is not a litigation exercise you begin when the letter arrives — it is a file you build before a single impression is served.

Keywords: advertising substantiation, prior substantiation, FTC Act Section 5, net impression, implied claims, puffery, establishment claims, competent and reliable scientific evidence, comparative advertising, Lanham Act Section 43(a), clear and conspicuous disclosure, Green Guides, Made in USA, consumer surveys, claim review workflow

How to use this checklist

This is a pre-publication workflow. It assumes you have creative in hand — a script, a landing page, a package, a paid social flight — and a launch date. Work the phases in order. Phases 1 through 4 apply to every campaign. Phases 5, 6, and 9 apply only if the campaign contains the claim types they govern; skip them if it does not, but read the trigger language before you skip, because advertisers routinely fail to notice they have made a health claim or a Made-in-USA claim at all.

For the doctrine behind the workflow — what "deceptive" means, who can sue, and what the remedies look like — read Advertising Law: A Comprehensive Guide to the FTC Act and Lanham Act alongside this. For the map of everything UpLaw publishes in this area, see The Advertising and Marketing Law Toolkit. If you are a founder or a small marketing team meeting this regime for the first time, start with Advertising Law for Small Businesses: A Practical FAQ and keep The Small Business Legal Toolkit open beside it — claim review is one gate among several that a launch has to clear.

Our running example. Verity Wellness is a direct-to-consumer brand about to launch Verity Recover, a topical magnesium gel for post-workout muscle soreness. Marketing wants a hero line: "Recover 3x faster." The launch is in six weeks. Everything below is applied to that claim.

Phase 1 — Inventory every claim: express, implied, and the net impression

  • [ ] Freeze a version of the creative (script, storyboard, comp, landing page, packaging dieline) and give it a version number. Substantiation attaches to a version, not a concept.
  • [ ] Extract every express claim — anything stated in words, on screen, in voiceover, or in copy. Put each in its own row of a claims matrix.
  • [ ] Extract every implied claim — what the ad conveys without saying. Read the headline against the visual; read the demo against the voiceover; read the before/after against the timeline shown.
  • [ ] Identify claims made by images, demonstrations, and mock-ups, not words. A demonstration is a claim that the demonstration is real.
  • [ ] Identify claims made by format: a white coat, a clipboard, a chart, a "clinically studied" badge, a lab bench.
  • [ ] Identify claims made by omission — a price with an unstated fee, a result with an unstated regimen, a testimonial with an unstated atypicality.
  • [ ] Write down, in one sentence, the net impression a reasonable consumer in the target audience takes away from the ad as a whole.
  • [ ] If the target audience is a vulnerable or specialized group (children, the seriously ill, the elderly, first-time borrowers), state the impression that audience takes away.
  • [ ] Circulate the claims matrix to someone who has not seen the creative before and ask what they think the product does. Record the answer verbatim.

Why it matters, and the traps

The FTC does not evaluate sentences; it evaluates advertisements. Under the FTC Policy Statement on Deception (1983), appended to Cliffdale Associates, Inc., 103 F.T.C. 110 (1984), an act or practice is deceptive if there is a representation, omission, or practice likely to mislead a consumer acting reasonably under the circumstances, and it is material. The representation is found in the ad's net impression — the whole, not the parts. A technically true headline sitting above a misleading chart is a deceptive ad.

Implied claims carry the same substantiation burden as express ones. In Kraft, Inc. v. FTC, 970 F.2d 311 (7th Cir. 1992), the Seventh Circuit upheld the Commission's finding that Kraft's Singles ads impliedly claimed the slices contained the calcium of five ounces of milk, even though no such sentence appeared; the Commission was permitted to find the implied claim from the face of the ad without extrinsic evidence. See also American Home Products Corp. v. FTC, 695 F.2d 681 (3d Cir. 1982). And demonstrations are claims: FTC v. Colgate-Palmolive Co., 380 U.S. 374 (1965), condemned the sandpaper-shave mock-up, where the "sandpaper" was plexiglass with sand on it — the product might have worked, but the proof offered to consumers was fake.

The trap. Teams inventory the headline and miss the ad. Verity's storyboard shows a runner icing a knee at 6:00 p.m., then jogging at 6:00 a.m. the next morning. Nobody wrote "recover overnight." The ad said it anyway. That implied claim needs support just like "3x faster" does.

Phase 2 — Classify each claim: objective fact, puffery, establishment claim, or health/safety claim

  • [ ] For each row in the matrix, mark objective (capable of being proven true or false) or puffery (subjective, exaggerated, non-quantifiable, not reasonably relied on).
  • [ ] Mark whether the claim is an establishment claim — one that says or implies that tests, studies, or experts prove the proposition ("clinically proven," "tests show," "doctor-recommended," "9 out of 10 dermatologists").
  • [ ] Mark whether the claim is a health, safety, disease, or efficacy claim (including structure/function and cosmetic-performance claims).
  • [ ] Mark whether the claim is comparative (against a named competitor, an unnamed competitor, a category, or the product's own prior formulation).
  • [ ] Mark whether the claim is quantified ("3x," "50% more," "up to 40%," "in 7 days").
  • [ ] Mark whether the claim is material — would it affect a consumer's purchase decision? Assume yes for anything about efficacy, price, safety, origin, or a central attribute.
  • [ ] Flag any claim that is puffery only because of a modifier ("we think," "arguably," "the best-tasting, in our opinion"). Modifiers rarely save a quantified claim.
  • [ ] Retire any claim you cannot support. Retirement is a legitimate outcome of this phase and is far cheaper than the alternative.

Why it matters, and the traps

Puffery is not a loophole; it is a narrow doctrine. "Better Ingredients. Better Pizza." survived as non-actionable puffery in Pizza Hut, Inc. v. Papa John's International, Inc., 227 F.3d 489 (5th Cir. 2000) — but only because it was a general, subjective boast, and the Fifth Circuit still held that the slogan could become actionable once it was fused with misleading comparative sauce-and-dough ads. The moment a boast acquires a number, a test, or a comparison, it leaves puffery behind.

Establishment claims are the highest-leverage classification in the whole matrix, because they change the object of proof. For an ordinary claim, you must have a reasonable basis for the proposition. For an establishment claim, you must have the very kind of proof you implied you had. Under Lanham Act § 43(a), 15 U.S.C. § 1125(a), a plaintiff attacking an establishment claim need not prove the underlying proposition false — it need only prove that the tests the advertiser cited do not establish it. See Castrol Inc. v. Quaker State Corp., 977 F.2d 57 (2d Cir. 1992); Castrol, Inc. v. Pennzoil Co., 987 F.2d 939 (3d Cir. 1993); Southland Sod Farms v. Stover Seed Co., 108 F.3d 1134 (9th Cir. 1997). That is a dramatically easier case for a competitor to bring, and it is why "clinically proven" is the most expensive two words in marketing.

The trap. Marketing wants to add "clinically proven" to "Recover 3x faster" because it "sounds more credible." It converts a claim Verity might substantiate with a reasonable basis into a claim Verity must prove with a specific, adequate clinical study of this product — and hands any competitor a literal-falsity theory if the study is thin.

Phase 3 — Determine the required level of substantiation

  • [ ] For each objective claim, ask first: what does the ad itself promise about the level of proof? If the ad says "two clinical trials show," the required level is two clinical trials. The advertiser sets its own floor.
  • [ ] If the ad makes no representation about the level of proof, apply the reasonable basis standard and work the Pfizer factors.
  • [ ] Document the Pfizer analysis on the record: (1) the product type; (2) the type of claim; (3) the benefit of a truthful claim; (4) the ease of developing substantiation; (5) the consequences of a false claim; (6) the amount of substantiation experts in the field would consider reasonable.
  • [ ] For any health, safety, or efficacy claim, escalate to competent and reliable scientific evidence (Phase 5).
  • [ ] Confirm the substantiation is claim-specific: the study must support this claim, for this product, in this population, at this dose, over this time frame.
  • [ ] Confirm the substantiation is product-specific or that you can articulate why an ingredient study extrapolates to the finished formulation (bioavailability, concentration, delivery vehicle, and duration all matter).
  • [ ] Record the person responsible for each row and the date the support was assembled.

Why it matters, and the traps

The framework comes from Pfizer, Inc., 81 F.T.C. 23 (1972), which established that failing to possess a reasonable basis for an objective claim is itself an unfair and deceptive act under FTC Act § 5, 15 U.S.C. § 45 — independent of whether the claim later turns out to be true. The FTC Policy Statement Regarding Advertising Substantiation (1984), appended to Thompson Medical Co., 104 F.T.C. 648 (1984), aff'd, 791 F.2d 189 (D.C. Cir. 1986), restates it: advertisers must have a reasonable basis before dissemination, and where the ad itself represents a particular level of support, the advertiser must possess that level.

The sliding scale is real. A claim that a stapler holds thirty sheets needs a bench test. A claim that a supplement reduces the duration of a cold needs human clinical evidence. The "ease of developing substantiation" factor cuts against advertisers in categories where testing is cheap and routine.

The trap — ingredient studies. Verity's file contains four papers on transdermal magnesium and delayed-onset muscle soreness. None of them tested Verity Recover. Two used a concentration Verity does not match. One was in a population of elite athletes. Ingredient literature is a starting point, not a substantiation file. Ask the hard question: would a qualified expert in the field, looking at this dossier, conclude that this product does what the ad says?

Phase 4 — Build the substantiation file BEFORE the ad runs (the prior-substantiation rule)

  • [ ] Open a dated substantiation file — one folder per campaign version, with an index.
  • [ ] Place in it, for each claim: the claim as written, the classification, the required level of proof, the supporting evidence, and a short memo explaining why the evidence supports the claim.
  • [ ] Include contrary evidence you are aware of and the reasoned explanation for why it does not defeat the claim. A file that contains only favorable data is not a reasonable basis; it is a marketing deck.
  • [ ] Capture the full study, not the abstract, not the press release, not the vendor's one-pager.
  • [ ] Date-stamp everything. Use a system where the date cannot be edited after the fact (document management, version control, or a signed and dated approval memo).
  • [ ] Have the reviewer sign the file with the date it was complete, and confirm that date is before the first dissemination date.
  • [ ] Preserve the file. Litigation-hold discipline applies: no auto-deletion of the substantiation folder, and no "cleaning up" the drafts.
  • [ ] Log the first-run date for every channel — TV, paid social, email, packaging, retail POS, affiliate copy — because each dissemination restarts the analysis for that version.

Why it matters, and the traps

This is the single most-violated rule in advertising law, and the one that most reliably converts a defensible claim into an indefensible case. The advertiser's obligation is to possess substantiation at the time the claim is made. Evidence assembled after a warning letter, a Civil Investigative Demand, or a competitor's cease-and-desist does not cure the violation, even if it is excellent evidence and even if the claim is true. That is the whole point of Pfizer and of the 1984 Substantiation Policy Statement.

There is a second, quieter benefit. A dated, indexed file is the artifact that lets outside counsel say "yes" quickly. A pile of PDFs in a shared drive is the artifact that makes counsel say "give us three weeks."

The trap — the file that grows backwards. Verity's team drafts the memo in week five, but the memo cites a study the company only licensed in week seven, after launch. In discovery, the license invoice tells that story better than the memo does. Build forward, date honestly, and if you are late, delay the ad — not the file.

Phase 5 — Health, safety, and efficacy claims: "competent and reliable scientific evidence"

  • [ ] Determine whether the claim touches food, drugs, devices, or cosmetics. If so, FTC Act § 12, 15 U.S.C. § 52, applies in addition to § 5, and FDA regimes may apply in parallel.
  • [ ] Apply the competent and reliable scientific evidence standard: tests, analyses, research, or studies conducted and evaluated in an objective manner by qualified persons, using procedures generally accepted in the profession to yield accurate and reliable results.
  • [ ] For a disease claim or a serious health claim, expect the benchmark to be human clinical testing — randomized, controlled, and ideally double-blinded, on the product or an adequately similar formulation.
  • [ ] Assess quality: sample size, control group, randomization, blinding, dropout rate, pre-registered endpoints, statistical significance, and whether the measured endpoint is the one the ad promises.
  • [ ] Assess quantity: is one study enough? Consider replication, the totality of the evidence, and whether the field expects more than one trial.
  • [ ] Assess fit: same population, same dose, same duration, same route of administration, same outcome measure.
  • [ ] Have a qualified independent expert review the dossier and put the review in writing, in the file, before launch.
  • [ ] Screen the copy for inadvertent disease claims ("relieves arthritis pain," "prevents flu") that convert a supplement or cosmetic into an unapproved drug claim.
  • [ ] Check applicable FTC guidance for the category, including the FTC's Health Products Compliance Guidance (2022).

Why it matters, and the traps

"Competent and reliable scientific evidence" is the operative phrase in nearly every FTC health-advertising order, and courts enforce it seriously. See Removatron International Corp. v. FTC, 884 F.2d 1489 (1st Cir. 1989); FTC v. National Urological Group, Inc., 645 F. Supp. 2d 1167 (N.D. Ga. 2008), aff'd, 356 F. App'x 358 (11th Cir. 2009). Note that the phrase is a standard, not a fixed protocol: what it demands is what qualified experts in the relevant field would accept for the specific proposition being advertised, which is why the same two words can mean a bench test in one category and a double-blind trial in another. At the same time, the standard has constitutional limits: in POM Wonderful, LLC v. FTC, 777 F.3d 478 (D.C. Cir. 2015), the D.C. Circuit upheld the Commission's finding of deception and its one-randomized-controlled-trial requirement for disease claims, but vacated a blanket two-RCT requirement as more extensive than necessary under the First Amendment. The lesson is not that RCTs are optional — it is that the required level of proof is calibrated to the claim.

Note also that FDA compliance is not a safe harbor from private suit. POM Wonderful LLC v. Coca-Cola Co., 573 U.S. 102 (2014), held that compliance with FDCA labeling rules does not preclude a competitor's Lanham Act false-advertising claim. Two regulators, two regimes, two sets of exposure.

Verity, applied. "Recover 3x faster" is an efficacy claim about the human body. It needs human data on Verity Recover, with a defined comparator ("faster than what?"), a validated soreness or recovery endpoint, and a magnitude that actually reaches 3x. If the study shows a statistically significant but 1.4x effect, the claim is dead — not softenable, not "up to"-able. Kill it or restate it to what the data shows.

Phase 6 — Comparative and superiority claims: the tests you must actually have run

  • [ ] Identify the comparator with precision. "3x faster" is meaningless until you answer: faster than nothing? Than rest? Than the leading brand? Than our old formula?
  • [ ] Make sure the comparator in the test is the comparator a consumer will understand from the ad. A head-to-head against a placebo does not support a head-to-head against a competitor.
  • [ ] Confirm the tested competitor product is the current version, purchased at retail, tested in the same run, under the same conditions.
  • [ ] Confirm the comparison is on an attribute consumers care about and that the ad does not imply superiority on attributes you did not test.
  • [ ] For "up to" claims, confirm a meaningful proportion of consumers will achieve the stated result under normal use.
  • [ ] For parity claims ("as effective as"), confirm the test was powered to show equivalence — a failure to find a difference is not proof of no difference.
  • [ ] Preserve raw data, protocols, statistical plans, and the lab's chain of custody. Assume a competitor's expert will re-analyze it.
  • [ ] Consider the National Advertising Division (NAD) of BBB National Programs as both a risk (a competitor challenge) and a tool (your own challenge). NAD moves in months, not years.
  • [ ] Assess exposure under Lanham Act § 43(a), 15 U.S.C. § 1125(a), including the standing analysis of Lexmark International, Inc. v. Static Control Components, Inc., 572 U.S. 118 (2014).

Why it matters, and the traps

Comparative advertising is where the FTC's regulatory exposure and the competitor's private cause of action converge — and the competitor is usually the faster, angrier plaintiff. Under § 43(a), a competitor may show literal falsity (no consumer survey required; the court reads the ad) or implied falsity (survey required to show actual deception). Courts also recognize falsity by necessary implication, where the ad, read as a whole, unambiguously conveys a false message even without stating it. See Time Warner Cable, Inc. v. DIRECTV, Inc., 497 F.3d 144 (2d Cir. 2007). For a practitioner's walk through the competitor side of this, see False Advertising Under Lanham Act Section 43(a): Competitor Claims in Tech Marketing.

The trap — the vanishing comparator. Verity's data compares Recover to no treatment. The ad, with a shelf of unbranded competitor tubes in the background, conveys "3x faster than the gel you're using now." Same number, entirely different claim, and no support for the one the ad actually makes. Either fix the creative or run the head-to-head.

Phase 7 — Consumer surveys, testing methodology, and expert support

  • [ ] Where the message is ambiguous or the stakes are high, run a copy test or perception survey to learn what consumers actually take away — before launch, not after.
  • [ ] Define the universe correctly: actual and prospective purchasers of the product category, not the general public.
  • [ ] Use a proper control — a stimulus identical to the ad but with the challenged element removed — so you can net out background noise.
  • [ ] Ask non-leading questions, in the right order, with "don't know" and "other" options.
  • [ ] Have the survey designed and executed by a qualified, independent expert who can withstand Daubert scrutiny under Fed. R. Evid. 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993).
  • [ ] Preserve the questionnaire, screener, verbatims, coding instructions, data file, and the interviewer instructions.
  • [ ] Understand that a copy test can create evidence against you. Scope it with counsel and consider privilege before you field it.
  • [ ] For lab and performance testing, pre-register the protocol, use accredited labs, and specify pass/fail criteria before the data comes in.

Why it matters, and the traps

The methodological rules that govern advertising surveys are the same rules that govern trademark confusion surveys, and the UpLaw materials on that subject transfer directly: Reading and Building Trademark Confusion Surveys: A Practical Guide to Expert Methodology explains universe, control, and format; Designing a Defensible Confusion Survey: A Practical Checklist gives you the build sequence; and Daubert and the Consumer Survey: A Practical Guide to Excluding Expert Testimony in Trademark Cases shows how the other side will attack it. A survey with no control group and a leading question is worse than no survey — it is a document your opponent gets to read to the jury.

The trap. Verity's brand team runs an unblinded "message resonance" study through the agency. Sixty percent of respondents say the ad tells them Recover is "3x faster than prescription treatment." Nobody tells legal. That document is discoverable, it is dated before launch, and it establishes that the company knew the net impression it was conveying.

Phase 8 — Disclosures and disclaimers: clear and conspicuous, and why fine print fails

  • [ ] First, ask the threshold question: can a disclosure fix this? A disclosure can qualify a claim; it cannot cure a false one. If the main message is false, no footnote saves it.
  • [ ] Place the disclosure on the same screen, page, and moment as the claim it qualifies. Not a footnote, not a hover, not "see details," not a link, not the next slide.
  • [ ] Meet the operative clear and conspicuous factors: prominence; presentation in a way consumers will notice, read, and understand; placement where consumers will look; and proximity to the triggering claim.
  • [ ] Match the modality: audio claims need audio disclosures; video claims need on-screen disclosures that stay up long enough to be read at normal reading speed.
  • [ ] Design for the smallest screen the ad will appear on, including muted, autoplaying, vertically cropped social video.
  • [ ] Avoid disclosures that contradict the main claim ("Recover 3x faster*" / "*Results not typical"). Contradiction is a confession, not a cure.
  • [ ] For testimonials and endorsements, disclose the generally expected results — the old "results not typical" safe harbor is gone under the FTC Endorsement Guides, 16 C.F.R. Part 255.
  • [ ] Disclose material connections with endorsers, employees, affiliates, and reviewers.
  • [ ] Apply the FTC's .com Disclosures guidance for digital and mobile placements.

Why it matters, and the traps

The Commission's position has hardened over two decades: a disclosure that a consumer does not see, cannot read, or does not understand does not exist. And a disclosure cannot rescue a deceptive net impression — that is the through-line from Colgate-Palmolive forward. On the endorsement side, the FTC's 2023 revision to Part 255 tightened the rules on incentivized reviews, employee endorsements, and platform responsibility. Work through the full endorsement workflow in Influencer and Endorsement Disclosure: A Practical Checklist.

The trap. Verity's paid social cut runs 6 seconds, muted, with the substantiation footnote in 9-point gray on a white background for 0.8 seconds. Functionally, the ad has no disclosure at all.

Phase 9 — Special claims: "Made in USA," green, pricing, and "free"

  • [ ] Made in USA. Unqualified U.S.-origin claims require that the product be "all or virtually all" made in the United States. Confirm final assembly in the U.S. and that all significant parts and processing are of U.S. origin, with negligible foreign content. See the Made in USA Labeling Rule, 16 C.F.R. Part 323, which carries civil penalty exposure. Consider a qualified claim ("Assembled in USA from imported components") if you cannot meet the standard. Check state statutes, which can be stricter.
  • [ ] Environmental claims. Avoid unqualified general benefit claims ("eco-friendly," "sustainable," "green"). Qualify narrowly and specifically, and hold substantiation for every attribute claimed. Apply the FTC Green Guides, 16 C.F.R. Part 260 — including the specific sections on degradable, compostable, recyclable, recycled content, carbon offsets, and "free of" claims.
  • [ ] Carbon and offset claims. Confirm the offsets are real, additional, verified, and not double-counted; disclose whether the emission reduction has already occurred or will occur years out.
  • [ ] Pricing claims. For "was/now," "compare at," and "regular price" claims, the former price must be a bona fide price at which the item was openly and actively offered for a reasonably substantial period. See the Guides Against Deceptive Pricing, 16 C.F.R. Part 233.
  • [ ] "Free." Disclose all conditions clearly and conspicuously and at the outset; do not recover the cost of the "free" item by raising the price of the required purchase. See 16 C.F.R. Part 251.
  • [ ] Bait advertising. Do not advertise a product you are unwilling or unable to sell as advertised. See 16 C.F.R. Part 238.
  • [ ] Negative options and "free trials." Disclose the material terms before billing information is collected, obtain express informed consent, and provide simple cancellation, per the Restore Online Shoppers' Confidence Act, 15 U.S.C. §§ 8401–8405.
  • [ ] AI and automation claims. "AI-powered" is now an enforcement priority; if the product's intelligence is a rules engine or a human in a call center, do not say otherwise. See Deploying an AI System: An AI Governance and Risk Checklist.

Why it matters, and the traps

Each of these regimes has its own definitional trapdoor, and each carries penalty exposure that ordinary § 5 cases often do not. They also sit on top of a state-law layer that is genuinely non-uniform: there is no single nationwide rule for origin, environmental, or pricing claims once you leave the federal guides. California, for example, has its own U.S.-origin statute with its own content thresholds, and several states police "sale" and "compare at" pricing more aggressively than the FTC does. Treat the federal framework as the floor and confirm the rule in each state where the ad will run. After AMG Capital Management, LLC v. FTC, 593 U.S. 67 (2021), the Commission cannot obtain equitable monetary relief under § 13(b) — which has pushed it toward rules with civil penalties (like Part 323), § 19 redress, and the Penalty Offense Authority under § 5(m)(1)(B). Translation: the categories with a rule attached are now the categories where the money is.

The trap. Verity's packaging says "Made in USA" because the tube is filled and boxed in Ohio. The magnesium is sourced abroad and the pump assembly is imported. "All or virtually all" is not met. The fix is a qualified claim, made before the print run, not after.

Phase 10 — Approval workflow, versioning, and maintaining the file for the campaign's life

  • [ ] Establish a single gate: no creative ships without a signed claim-review approval tied to a version number.
  • [ ] Require legal or regulatory sign-off on the claims matrix, not just the finished ad.
  • [ ] Re-run the review on every material revision, and on every adaptation to a new channel, length, or market. A 30-second spot cut down to 6 seconds is a new ad.
  • [ ] Re-run the review whenever the product changes — reformulation, new supplier, new manufacturing site, new dose.
  • [ ] Re-run the review whenever the evidence changes — a new study contradicts the old one, a supplier's certificate lapses, an endorser's credential expires.
  • [ ] Set a calendar review (quarterly is typical) for evergreen claims on packaging, the website, and always-on paid media.
  • [ ] Push claim discipline downstream: affiliates, resellers, distributors, retail partners, and influencers repeat your claims. Contract for it, supply approved copy, and monitor.
  • [ ] Keep the file for the life of the campaign plus the applicable limitations period. Three years after the last dissemination is a common floor; longer where a consent order or a state statute reaches further.
  • [ ] Build the claim gate into the broader launch process. See Launching a Website: A Legal Compliance Checklist for the surrounding compliance work.

Why it matters, and the traps

Substantiation is a continuing obligation. The claim on the website today is a claim made today, supported by the evidence you possess today. Advertisers get into trouble not because they never had substantiation, but because they had it in 2023, reformulated the product in 2024, and never touched the copy.

The trap — the orphan asset. Verity retires "3x faster" from paid media but leaves it on the product detail page, in a 2024 press release still live on the site, and on 40,000 tubes sitting in a distributor's warehouse. Every one of those is a live dissemination.

Common mistakes to avoid

  1. Substantiating the sentence instead of the ad. The net impression governs. The FTC and a competitor will both read the whole thing.
  2. Treating "up to" as a magic qualifier. "Up to 3x faster" still needs a meaningful proportion of users to reach 3x.
  3. Using ingredient literature as product substantiation without a fit analysis on dose, formulation, population, and endpoint.
  4. Adding "clinically proven" for tone. It converts an ordinary claim into an establishment claim and hands a competitor a literal-falsity theory.
  5. Building the file after the letter arrives. Prior substantiation means prior. Post-hoc evidence does not cure the violation.
  6. Filing only the favorable studies. A reasonable basis requires that you consider and address contrary evidence.
  7. Assuming FDA compliance immunizes you. POM Wonderful LLC v. Coca-Cola Co., 573 U.S. 102 (2014), says otherwise as to competitor suits.
  8. Relying on the disclaimer to fix a false main claim. Disclosures qualify; they do not cure.
  9. Testing against the wrong comparator, or against a competitor product version no longer on the shelf.
  10. Letting agencies, affiliates, and influencers write claims with no approved-copy discipline and no monitoring. Advertisers are responsible for what their partners say on their behalf.
  11. Ignoring the orphan channels — packaging, PDP copy, retail signage, old blog posts, and the App Store listing.
  12. Fielding an unblinded copy test with no counsel involvement, and creating the best piece of evidence the plaintiff will ever get.

The consolidated substantiation checklist

Inventory

  • [ ] Creative frozen and versioned
  • [ ] Every express claim captured
  • [ ] Every implied claim captured (visuals, demos, formats, omissions)
  • [ ] Net impression written in one sentence
  • [ ] Target-audience perspective applied

Classify

  • [ ] Objective vs. puffery marked
  • [ ] Establishment claims flagged
  • [ ] Health/safety/efficacy claims flagged
  • [ ] Comparative and quantified claims flagged
  • [ ] Materiality assessed
  • [ ] Unsupportable claims retired

Level of proof

  • [ ] Ad's own representation of proof identified and matched
  • [ ] Pfizer reasonable-basis factors documented
  • [ ] Claim-specific and product-specific fit confirmed

File

  • [ ] Dated, indexed substantiation file opened per version
  • [ ] Full studies (not abstracts) included
  • [ ] Contrary evidence addressed in writing
  • [ ] Reviewer signature dated before first dissemination
  • [ ] First-run dates logged per channel

Health and efficacy

  • [ ] Competent and reliable scientific evidence standard applied
  • [ ] Human clinical support where the claim requires it
  • [ ] Quality, quantity, and fit assessed
  • [ ] Independent expert review in the file
  • [ ] No inadvertent disease claims

Comparative

  • [ ] Comparator defined and matched to consumer understanding
  • [ ] Current competitor product tested
  • [ ] Raw data, protocol, and statistical plan preserved
  • [ ] "Up to" and parity claims stress-tested
  • [ ] Lanham Act § 43(a) and NAD exposure assessed

Surveys and testing

  • [ ] Universe, control, and non-leading questions
  • [ ] Qualified independent expert; Daubert-ready
  • [ ] All survey materials preserved
  • [ ] Copy-test scope discussed with counsel

Disclosures

  • [ ] Disclosure qualifies rather than contradicts
  • [ ] Same screen, same moment, adequate duration
  • [ ] Modality matched (audio/audio, video/on-screen)
  • [ ] Mobile and muted-autoplay tested
  • [ ] Endorsement and material-connection disclosures in place

Special regimes

  • [ ] Made in USA: "all or virtually all" or a qualified claim
  • [ ] Green Guides applied; no unqualified general benefit claims
  • [ ] Pricing: bona fide former price
  • [ ] "Free": all conditions disclosed up front
  • [ ] Negative option: ROSCA compliance

Workflow

  • [ ] Single approval gate tied to a version number
  • [ ] Re-review on creative, product, or evidence change
  • [ ] Calendar review for evergreen claims
  • [ ] Downstream partners contracted and monitored
  • [ ] File retained through the limitations period

Primary Authority

Statutes

  • Federal Trade Commission Act § 5, 15 U.S.C. § 45 (unfair or deceptive acts or practices; civil penalties under § 45(l) and (m))
  • Federal Trade Commission Act § 12, 15 U.S.C. § 52 (false advertisements for food, drugs, devices, services, and cosmetics)
  • Federal Trade Commission Act § 19, 15 U.S.C. § 57b (consumer redress)
  • Lanham Act § 43(a), 15 U.S.C. § 1125(a) (false advertising; competitor standing)
  • Restore Online Shoppers' Confidence Act, 15 U.S.C. §§ 8401–8405 (negative options and free trials)

Regulations and FTC guidance

  • FTC Policy Statement Regarding Advertising Substantiation (1984), appended to Thompson Medical Co., 104 F.T.C. 648 (1984), aff'd, 791 F.2d 189 (D.C. Cir. 1986)
  • FTC Policy Statement on Deception (1983), appended to Cliffdale Associates, Inc., 103 F.T.C. 110 (1984)
  • FTC Guides Concerning the Use of Endorsements and Testimonials in Advertising, 16 C.F.R. Part 255
  • FTC Guides for the Use of Environmental Marketing Claims (Green Guides), 16 C.F.R. Part 260
  • Made in USA Labeling Rule, 16 C.F.R. Part 323; FTC Enforcement Policy Statement on U.S. Origin Claims (1997)
  • Guides Against Deceptive Pricing, 16 C.F.R. Part 233
  • Guide Concerning Use of the Word "Free" and Similar Representations, 16 C.F.R. Part 251
  • Guides Against Bait Advertising, 16 C.F.R. Part 238
  • FTC, .com Disclosures: How to Make Effective Disclosures in Digital Advertising
  • FTC, Health Products Compliance Guidance (2022)

Cases

Secondary sources

  • Restatement (Third) of Unfair Competition §§ 2–3 (deceptive marketing)
  • McCarthy on Trademarks and Unfair Competition (false advertising chapters)
  • BBB National Programs, National Advertising Division case decisions (self-regulatory precedent on substantiation and comparative claims)

State consumer-protection statutes — for example, California's Unfair Competition Law and False Advertising Law, Cal. Bus. & Prof. Code §§ 17200 and 17500, and the "little FTC Acts" in every state — run in parallel and often reach conduct the FTC does not pursue. Some, like California's U.S.-origin statute, Cal. Bus. & Prof. Code § 17533.7, impose their own standards. Confirm your own state's rule before relying on the federal framework alone.

Related UpLaw Resources

Related Guides & Articles

Related Checklists

Related Toolkits

This checklist is general legal information from UpLaw (uplaw.us), not legal advice, and does not create an attorney-client relationship. Laws vary by state and change over time; verify current requirements and consult qualified counsel before acting.